9 To 11 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.6)
-
Publication number: 20120071399Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner.Type: ApplicationFiled: June 28, 2011Publication date: March 22, 2012Applicant: ENZO BIOCHEM, INC.Inventors: JOSHUA RABBANI, JAMES J. DONEGAN, XIAOFENG LI
-
Publication number: 20120065131Abstract: The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably the positively charged carrier is a long-chain positively charged polypeptide or a positively charged nonpeptidyl polymer, for example, a polyalkyleneimine. The invention further relates methods for producing a biologic effect of reducing synaptic transmission in a tissue by topically applying an effective amount of such a composition, preferably to the skin, of a subject or patient in need of such treatment.Type: ApplicationFiled: August 29, 2011Publication date: March 15, 2012Applicant: Revance Therapeutics, Inc.Inventors: Michael D. Dake, Jacob M. Waugh
-
Publication number: 20120058137Abstract: The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells. The present invention also relates to manufacture of said transporter cargo conjugate molecules, to a method of transporting a substance of interest (cargo) into a white blood cell and to a white blood cell comprising said transporter cargo conjugate molecules or fragments thereof.Type: ApplicationFiled: December 22, 2009Publication date: March 8, 2012Applicant: XIGEN, S.A.Inventor: Christophe Bonny
-
Publication number: 20120058933Abstract: The present invention provides Parotid Secretory Protein peptides, nucleic acids encoding the peptides, and methods of using the peptides, and methods of screening GL13 mimetics.Type: ApplicationFiled: May 8, 2008Publication date: March 8, 2012Applicant: University of Louisville Research FoundationInventor: Sven-Ulrik Gorr
-
Patent number: 8129345Abstract: The disclosure provides methods of identifying and making compounds and pharmaceutical compositions containing the compounds that inhibit the interaction between MUC1 and an IKK. The disclosure also provides in vivo and in vitro methods of inhibiting such an interaction. Also embraced by the disclosure are in vitro and in vivo methods of inhibiting the IKK/NF-?B pathway in cells expressing MUC1. The compounds, compositions, and methods of the disclosure are generally useful in the treatment of various cancers, inflammatory (e.g., autoimmune disorders), and transplant rejection.Type: GrantFiled: July 20, 2007Date of Patent: March 6, 2012Assignee: Dana-Farber Cancer Institute, Inc.Inventor: Donald W. Kufe
-
Patent number: 8129330Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: GrantFiled: September 25, 2003Date of Patent: March 6, 2012Assignee: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L Martinez, Merry R Sherman, Mark G. P. Saifer, L. David Williams
-
Publication number: 20120052116Abstract: The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.Type: ApplicationFiled: April 19, 2010Publication date: March 1, 2012Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-Yok Tsang, Ira Pastan
-
Patent number: 8124051Abstract: The present invention relates to compositions and methods for producing a complex drug delivery system which specifically targets cancer cells, has an increase in cellular uptake, is cytotoxic, and suppresses antiapoptotic cellular defenses.Type: GrantFiled: June 27, 2008Date of Patent: February 28, 2012Assignee: Rutgers, The State University of New JerseyInventors: Tamara Minko, Patrick J. Sinko, Stanley Stein
-
Publication number: 20120045394Abstract: The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed.Type: ApplicationFiled: November 1, 2011Publication date: February 23, 2012Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Wadih Arap, Renata Pasqualini
-
Publication number: 20120045393Abstract: The invention is directed to analogs of LHRH-II and, more generally, to analogs of the LHRH family in which modifications have been made that confer enhanced binding affinity for LHRH receptors and/or improved metabolic stability. The invention is further directed to methods of targeted therapy and targeted imaging in patients with sex-hormone-related cancers or other LHRH-mediated diseases.Type: ApplicationFiled: March 16, 2010Publication date: February 23, 2012Inventors: Karen E. Linder, Palaniappa Nanjappan, Natarajan Raju, Sudha Khurana, Rolf E. Swenson, Adrian D. Nunn, Kondareddiar Ramalingam
-
Publication number: 20120045411Abstract: The invention is directed to beta-defensin-derived peptides and their use in modulating the activity of hematopoietic cells and other CXCR4-expressing cells. Specifically, the invention provides compositions and methods useful in the treatment of cancer. The invention further provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells.Type: ApplicationFiled: February 10, 2010Publication date: February 23, 2012Applicant: Yeda Research and Development Co., Ltd.Inventors: Tsvee Lapidot, Alexander Kalinkovich, Matityahu Fridkin
-
Publication number: 20120040918Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.Type: ApplicationFiled: March 13, 2009Publication date: February 16, 2012Applicant: CTI BIOInventors: Jong-Ook Lee, Shin Chung, Heui-Yeon Kim, Hyun-Jin Park, Mi-Ran Kim
-
Publication number: 20120040915Abstract: Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.Type: ApplicationFiled: August 1, 2011Publication date: February 16, 2012Inventors: Debabrata Mukhopadhyay, Priyabrata Mukherjee, Mark Spaller
-
Publication number: 20120039801Abstract: Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide—Antibody Fc domain fusion proteins and methods of their use are disclosed.Type: ApplicationFiled: December 7, 2009Publication date: February 16, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Patent number: 8114406Abstract: The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.Type: GrantFiled: June 28, 2010Date of Patent: February 14, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: David D. Roberts, Henry C. Krutzsch
-
Patent number: 8114407Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.Type: GrantFiled: October 22, 2007Date of Patent: February 14, 2012Inventors: Walter J. Storkus, Michael S. Kinch
-
Patent number: 8110554Abstract: A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. Cleavage of X allows separation of A from B, unmasking the normal ability of the basic amino acids in B to drag cargo C into cells near the cleavage event. X is cleaved extracellularly, preferably under physiological conditions. D-amino acids are preferred for the A and B portions, to minimize immunogenicity and nonspecific cleavage by background peptidases or proteases.Type: GrantFiled: October 2, 2008Date of Patent: February 7, 2012Assignee: The Regents of the University of CaliforniaInventors: Tao Jiang, Roger Y. Tsien
-
Patent number: 8110654Abstract: The present invention provides two T-cell epitode peptides of anti-idiotype antibody 6B11 of ovarian cancer, the sequences of which are shown in SEQ ID NO:3 or 6. The present invention also provides the use of such T-cell epitope peptides in the manufacture of vaccines against ovarian cancer and in the treatment and prevention of ovarian cancer. The T-cell epitope peptides of the present invention could specifically kill ovarian cancer cells which are OC166-9 positive, and could find a wide use in the treatment and prevention of ovarian cancer.Type: GrantFiled: June 4, 2007Date of Patent: February 7, 2012Assignee: Peking University People;s HospitalInventors: Heng Cui, Wei Li, Xiaohong Chang, Jie Feng, Hongyan Cheng, Huifang Guo, Yexia Cheng
-
Publication number: 20120028913Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.Type: ApplicationFiled: October 17, 2011Publication date: February 2, 2012Applicant: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon
-
Publication number: 20120028912Abstract: The present invention features compounds useful for and methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods for treating HIV infection and HIV related disease.Type: ApplicationFiled: November 2, 2009Publication date: February 2, 2012Inventors: Ming-Ming Zhou, Aneel K. Aggarwal, Melanie Ott, Eric Verdin
-
Publication number: 20120028888Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.Type: ApplicationFiled: November 4, 2009Publication date: February 2, 2012Inventors: Jay Janz, Athan Kuliopulos, Thomas J. McMurry
-
Patent number: 8105604Abstract: The present invention discloses a cancer antigen peptide comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), a cancer vaccine having this for its active ingredient, and a DNA vaccine having for its active ingredient DNA that codes for this peptide.Type: GrantFiled: September 2, 2009Date of Patent: January 31, 2012Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Publication number: 20120020882Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: ApplicationFiled: August 8, 2011Publication date: January 26, 2012Applicant: GE HEALTHCARE ASInventors: Alan Cuthbertson, Bard Indrevoll, Magne Solbakken, Torgrim Engell, Colin Mill Archer, Harry John Wadsworth
-
Publication number: 20120020881Abstract: This invention relates to novel compounds suitable for labeling by positron emitting isotopes, such as 18F, 11C, 13N and 15O, through appropriate labeling reagents, such as 18F reagents and methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).Type: ApplicationFiled: December 4, 2009Publication date: January 26, 2012Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Lutz Lehmann, Timo Stellfeld, Keith Graham, Jessica Becaud, Linjing Mu
-
Patent number: 8101580Abstract: It was shown that bombesin 2 (BB2) receptor antagonists typified by RC-3095 are therapeutic agents for irritable bowel syndrome (IBS), and show excellent efficacy in treating both an abdominal symptom and bowel movement disorder. Thus, the present invention provides a therapeutic agent for irritable bowel syndrome (IBS) which comprises, as an active ingredient, a bombesin 2 (BB2) receptor antagonist as well as a method for treating IBS.Type: GrantFiled: April 19, 2006Date of Patent: January 24, 2012Assignee: Astellas Pharma Inc.Inventor: Mayumi Yamano
-
Patent number: 8101186Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: GrantFiled: February 16, 2007Date of Patent: January 24, 2012Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
-
Patent number: 8101578Abstract: The present invention provides a peptide which functions as a mimic peptide of an amyloid ? peptide and is capable of inhibiting the fibrillogenesis of an amyloid ? peptide. The present invention relates to: an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (I): X1-Asp-X2-X3-X4-Pro-X5-X6 (SEQ ID NO: 28)??(I) wherein X1 represents a branched chain amino acid, and X2, X3, X4, X5, and X6 are the same or different and each represents an ?-amino acid; a 9- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (III): Z1-X13-Gly-X14-X15-Pro-Trp-Met-Z2 (SEQ ID NO: 31)??(III) wherein X13, X14, and X15 are the same or different and each represents an ?-amino acid, Z1 and Z2 are the same or different and each represents cysteine or serine, and when Z1 and Z2 represent cysteine, they may be crosslinked; and a pharmaceutical composition and an amyloid ? fibrillogenesis inhibitor comprising the peptide.Type: GrantFiled: April 24, 2007Date of Patent: January 24, 2012Assignee: Kagoshima UniversityInventor: Kazuhisa Sugimura
-
Publication number: 20120015873Abstract: The present invention finds application in the therapeutic fields. In particular, it concerns new synthetic melanocortin peptides having improved antimicrobial activity.Type: ApplicationFiled: January 19, 2009Publication date: January 19, 2012Inventors: Anna Catania, Ferruccio Bonino, Paolo Grieco, Ettore Novellino
-
Publication number: 20120014925Abstract: The invention relates to a novel class of self-assembling peptides, compositions thereof, methods for the preparation thereof and methods of use thereof. The invention also encompasses methods for tissue regeneration, increasing the production of extracellular matrix proteins, and methods of treatment comprising administering self-assembling peptides.Type: ApplicationFiled: July 16, 2010Publication date: January 19, 2012Inventors: Yoshiyuki Kumada, Shuguang Zhang
-
Publication number: 20120015868Abstract: The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.Type: ApplicationFiled: June 29, 2011Publication date: January 19, 2012Applicant: Takeda Pharmaceutical Company LimitedInventors: Chieko Kitada, Taiji Asami, Naoko Nishizawa, Tetsuya Ohtaki, Naoki Tarui, Hirokazu Matsumoto, Jiro Noguchi, Hisanori Matsui
-
Publication number: 20120010142Abstract: This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Inventors: John C. Burnett, JR., Timothy M. Olson
-
Publication number: 20120009123Abstract: The invention provides compositions and methods for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to an albumin binding peptide and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 7, 2009Publication date: January 12, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20120010151Abstract: The present invention relates to a novel unbranched carbamate derivative, in particular N-butyloxycarbonyl derivative of certain Wnt5-? peptides and to their use in the treatment of melanoma or gastric cancer, as well as a method for treating melanoma as well as a pharmaceutical composition comprising the same derivative.Type: ApplicationFiled: August 13, 2009Publication date: January 12, 2012Inventor: Tommy Andersson
-
Publication number: 20120004182Abstract: The present invention relates to methods for inducing and/or enhancing apoptosis in pathogenic cells. In particular, the present invention relates to the use of GnRH II antagonists in combination with at least one further compound selected from the group of selective estrogen receptor modulators (SERM), Aromatase inhibitors, and glycolysis inhibitors or salts or solvates thereof for inducing and/or enhancing apoptosis of specific types of tumor cells, expressing the GnRH II receptor as well as to methods relating thereto.Type: ApplicationFiled: July 2, 2010Publication date: January 5, 2012Inventors: CARSTEN GRUENDKER, GUENTER EMONS
-
Publication number: 20110318433Abstract: The present invention relates to a soothing cosmetic or pharmaceutical composition comprising at least one peptide that activates human HMG-CoA reductase of general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AA)p-R2 and a physiologically suitable medium. The present invention further relates to the utilization of this novel peptide as a soothing active principle in a cosmetic composition. The invention further applies to a cosmetic treatment method intended to combat skin irritations.Type: ApplicationFiled: December 23, 2009Publication date: December 29, 2011Applicant: ISP INVESTMENTS INC.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20110311446Abstract: A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed.Type: ApplicationFiled: July 14, 2011Publication date: December 22, 2011Applicants: Bracco Suisse SA, Dyax Corp.Inventors: Daniel T. Dransfield, Aaron Sato, Robert Charles Ladner, Palaniappa Nanjappan
-
Patent number: 8080262Abstract: The present invention provides compositions and methods for creating encapsulated peptide amphiphilic nanostructures useful in treating diseases. In particular, the present invention provides compositions and methods for preparing peptide amphiphile nanostructures that are encapsulated in liposomes by the application of light, and using such compositions in treating diseases, such as cancer.Type: GrantFiled: October 24, 2007Date of Patent: December 20, 2011Assignee: Northwestern UniversityInventors: Hyung-Kun Lee, Stephen Soukasene, Samuel I. Stupp
-
Patent number: 8080252Abstract: A method of modulating angiogenesis in a tissue comprises administering to the tissue a therapeutically effective amount of an agent that modulates complex formation of ?v?3 integrin and VEGFR2.Type: GrantFiled: January 21, 2009Date of Patent: December 20, 2011Assignee: The Cleveland Clinic FoundationInventors: Tatiana Byzova, Ganapati H. Maha Baleshuar, Weiyi Feng
-
Publication number: 20110306565Abstract: Pharmaceutical compositions are provided for enhancing the therapeutic effect of biologically active peptides, especially peptides derived from human lactoferrin. The compositions are useful for the treatment and/or prevention of wounds, scars, and post surgical adhesions.Type: ApplicationFiled: January 12, 2010Publication date: December 15, 2011Inventors: Margit Mahlapuu, Mattias Münnich
-
Publication number: 20110306545Abstract: The present invention relates to new peptides, pharmaceutical composition and cosmetic composition including them and their use for wound healing.Type: ApplicationFiled: June 14, 2010Publication date: December 15, 2011Applicant: GENE SIGNAL INTERNATIONAL SAInventors: Salman Al-Mahmood, Sylvie Colin
-
Publication number: 20110305632Abstract: The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), compounds useful as synthetic intermediates in the method, new bis(thiosemicarbazones) that can be readily accessed by use of the method and methods of treatment and imaging utilising some of the new bis(thiosemicarbazones).Type: ApplicationFiled: December 11, 2009Publication date: December 15, 2011Applicant: THE UNIVERSITY OF MELBOURNEInventors: Paul Stephen Donnelly, Brett Michael Paterson
-
Publication number: 20110306554Abstract: The present invention provides a peptide capable of binding to an immunoglobulin, a fusion protein with the peptide, nucleic acids coding for the peptide and for the fusion protein, methods for producing the peptide and the fusion protein, and a composition and means for binding an immunoglobulin, as well as a pharmaceutical composition for the treatment or prevention of a disease caused by the binding between C1q and an immunoglobulin, which includes a peptide capable of binding to the immunoglobulin or a fusion protein with the peptide, and others.Type: ApplicationFiled: January 19, 2010Publication date: December 15, 2011Inventor: Osamu Masaki
-
Patent number: 8076300Abstract: FGF2-binding peptides are here described, which have been designed starting from the N-terminal region of PTX3, in particular spanning the PTX3(82-11O) region. Synthetic peptides related to this sequence are able to bind FGF2 and to inhibit its pro-angiogenic activity in vitro and in vivo with no anticipated impact on innate immunity.Type: GrantFiled: January 23, 2007Date of Patent: December 13, 2011Assignee: Tecnogen S.p.A.Inventors: Marco Presta, Maura Camozzi, Marco Rusnati, Maurizio Colombo, Domenico Mastroianni
-
Patent number: 8076284Abstract: Antimicrobial and anticancer peptides engineered using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have a smaller structure compared with previously known Gaegurin peptides and show potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptides synthesized from the shortest length of Gaegurin 5, show potent antimicrobial activity against gram positive and negative strains, good safety with very low hemolytic activity and favorable advantages such as drug absorption and drug transportation due to its advantageous structural property, which can be useful as a potent antimicrobial or anticancer agent.Type: GrantFiled: May 14, 2007Date of Patent: December 13, 2011Assignee: Promeditech, Inc.Inventors: Bong Jin Lee, Min Duk Seo, Su Jin Kang, Hyun Jung Kim
-
Patent number: 8076453Abstract: The present invention provides for novel kinin B1 receptors peptide agonists of formula (I) having very good to excellent affinities and selectivity for the B1 receptor, in vitro and in vivo increased resistance to enzymatic degradation, superior pharmacokinetic properties to those of naturally occurring agents, capacity to significantly enhance delivery of chemotherapeutic substances across the blood brain barrier and within peripheral tissues for the treatment of tumors, capacity to protect and restore kidney, heart, brain and other organ functions, when given alone or in combination with other therapies in the treatment of hypertension, diabetes and other cardiovascular diseases particularly, but not limited to, atherosclerosis and arteriosclerosis. Formula (I): aay-aax-aa0-aa1-aa2-aa3-aa4-aa5-Ser6-Pro7-D-Phe8-X.Type: GrantFiled: May 31, 2006Date of Patent: December 13, 2011Assignee: Societe De Commercialisation Des Produits De La Recheche Appliquee-Socpra-Science Sante Et Humaines S.E.C.Inventors: Fernand Gobeil, Jr., Witold A. Neugebauer, Domenico Regoli, David Fortin
-
Publication number: 20110301101Abstract: This invention is related to a peptides mixture. Without the need to consider the patients' genetic background, it can interfere with MHC-pathogenic peptide-TCR formation, which includes the interference with pathogen peptide binding with MHC and pMHC binding with specific TCR, suppression of the immune synapse formation when the specific T cell immune response occurs, reduction of the number and density of the MHC-specific immune response mediated pathogenic peptide-TCR in the immune synapse, and suppression of the highly activated signal transduction in the immune synapse. Hence it can negatively regulate the T cell specific immune response, reduce the specific immune cell activation, proliferation and effect, and make the radical T cell specific immune response more stable and last longer. It can be used to treat diseases with excessive T cell-specific immune reaction, such as severe flu, SARS, hand-foot-and-mouth disease, viral pneumonia, bacterial infections, severe autoimmune disease and etc.Type: ApplicationFiled: September 28, 2010Publication date: December 8, 2011Inventor: Shuqi Xia
-
Publication number: 20110300141Abstract: A protein kinase C inhibitor that binds B-amyloid and its peptide derivatives with the same function are disclosed. These may be useful in the treatment of Alzheimer's disease, for example as pseudo vaccines comprising antibodies, or as part of fusion proteins which are able to pass through cell membranes or through the blood-brain barrier. Methods of using the PKC inhibitor and its peptide derivatives for treating Alzheimer's disease are also disclosed.Type: ApplicationFiled: June 16, 2006Publication date: December 8, 2011Inventor: Balu Chakravarthy
-
Patent number: 8071538Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: GrantFiled: August 23, 2010Date of Patent: December 6, 2011Inventors: Hq Han, Hosung Min, Thomas C. Boone
-
Patent number: 8071554Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.Type: GrantFiled: August 7, 2006Date of Patent: December 6, 2011Assignee: Araim Pharmaceuticals, Inc.Inventors: Anthony Cerami, Michael Brines
-
Publication number: 20110293641Abstract: A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 79, SEQ ID NO 82, SEQ ID NO 85, SEQ ID NO 88, SEQ ID NO 91, SEQ ID NO 94, SEQ ID NO 97, SEQ ID NO 100, SEQ ID NO 103, SEQ ID NO 106, SEQ ID NO 109, SEQ ID NO 112, or SEQ ID NO 115. The peptide may comprise a delivery sequence such as a cationic peptide.Type: ApplicationFiled: November 17, 2009Publication date: December 1, 2011Inventors: Andrew Graham Bowie, Barry Noel Harrington, Tatyana Sergeevna Lysakova, Brian Keogh